David Loew, Ipsen CEO (Ipsen via Twitter)
February 11, 2022 11:00 AM EST
Pharma

Hunt­ing more R&D deals, Ipsen is ham­mer­ing out a $460M sale of con­sumer ops while cut­ting costs

John Carroll

Editor & Founder

These days, con­sumer health di­vi­sions rep­re­sent a con­ve­nient source of cash as phar­ma play­ers dou­ble down on their R&D op­er­a­tions and hunt new deals. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

2024's bio­phar­ma win­ners and losers; Ca­griSe­ma falls short; Mer­ck swings Chi­na GLP-1 deal; and more

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times